[1]
|
Ponka, P. and Lok, C.N. (1999) The Transferrin Receptor: Role in Health and Disease. The International Journal of Biochemistry & Cell Biology, 31, 1111-1137. https://doi.org/10.1016/S1357-2725(99)00070-9
|
[2]
|
Young, S.P., Bomford, A. and Williams, R. (1984) The Effect of the Iron Saturation of Transferrin on Its Binding and Uptake by Rabbit Reticulocytes. Biochemical Journal, 219, 505-510. https://doi.org/10.1042/bj2190505
|
[3]
|
Beutler, E., Gelbart, T., Lee, P., et al. (2000) Molecular Characterization of a Case of Atransferrinemia. Blood, 96, 4071-4074. https://doi.org/10.1182/blood.V96.13.4071
|
[4]
|
Lecureuil, C. (2004) Transgenic Mice as a Model to Study the Regulation of Human Transferrin Expression in Sertoli Cells. Human Reproduction, 19, 1300-1307. https://doi.org/10.1093/humrep/deh297
|
[5]
|
Tsutsumi, M., Skinner, M.K. and Sanders-Bush, E. (1989) Transferrin Gene Expression and Synthesis by Cultured Choroid Plexus Epithelial Cells. Journal of Biological Chemistry, 264, 9626-9631. https://doi.org/10.1016/S0021-9258(18)60576-9
|
[6]
|
Bloch, B., Popovici, T., Levin, M.J., et al. (1985) Transferrin Gene Expression Visualized in Oligodendrocytes of the Rat Brain by Using in Situ Hybridization and Immunohistochemistry. Proceedings of the National Academy of Sciences, 82, 6706-6710. https://doi.org/10.1073/pnas.82.19.6706
|
[7]
|
Gomme, P.T., McCann, K.B. and Bertolini, J. (2005) Transferrin: Structure, Function and Potential Therapeutic Actions. Drug Discovery Today, 10, 267-273. https://doi.org/10.1016/S1359-6446(04)03333-1
|
[8]
|
Inoue, T., Cavanaugh, P.G., Steck, P.A., et al. (1993) Differences in Transferrin Response and Numbers of Transferrin Receptors in Rat and Human Mammary Carcinoma Lines of Different Metastatic Potentials. Journal of Cellular Physiology, 156, 212-217. https://doi.org/10.1002/jcp.1041560128
|
[9]
|
Jing, S.Q. and Trowbridge, I.S. (1987) Identification of the Intermolecular Disulfide Bonds of the Human Transferrin Receptor and Its Lipid-Attachment Site. The EMBO Journal, 6, 327-331. https://doi.org/10.1002/j.1460-2075.1987.tb04758.x
|
[10]
|
Daniels, T.R., Delgado, T., Rodriguez, J.A., et al. (2006) The Transferrin Receptor Part I: Biology and Targeting with Cytotoxic Antibodies for the Treatment of Cancer. Clinical Immunology, 121, 144-158. https://doi.org/10.1016/j.clim.2006.06.010
|
[11]
|
Trowbridge, I.S. (1988) Transferrin Receptor as a Potential Therapeutic Target. In: Waldmann, H., Ed., Chemical Immunology and Allergy, S. Karger AG, Basel, 121-146. https://doi.org/10.1159/000416377
|
[12]
|
Panaccio, M., Zalcberg, J.R., Thompson, C.H., et al. (1987) Heterogeneity of the Human Transferrin Receptor and Use of Anti-Transferrin Receptor Antibodies to Detect Tumours in vivo. Immunology & Cell Biology, 65, 461-472. https://doi.org/10.1038/icb.1987.55
|
[13]
|
Gross, S., Helm, K., Gruntmeir, J.J., et al. (1997) Characterization and Phenotypic Analysis of Differentiating CD34 Human Bone Marrow Cells in Liquid Culture. European Journal of Haematology, 59, 318-326. https://doi.org/10.1111/j.1600-0609.1997.tb01693.x
|
[14]
|
Mojarad-Jabali, S., Mahdinloo, S., Farshbaf, M., et al. (2022) Transferrin Receptor-Mediated Liposomal Drug Delivery: Recent Trends in Targeted Therapy of Cancer. Expert Opinion on Drug Delivery, 19, 685-705. https://doi.org/10.1080/17425247.2022.2083106
|
[15]
|
Walker, R.A. and Day, S.J. (1986) Transferrin Receptor Expression in Non-Malignant and Malignant Human Breast Tissue. The Journal of Pathology, 148, 217-224. https://doi.org/10.1002/path.1711480305
|
[16]
|
Smith, N.W., Strutton, G.M., Walsh, M.D., et al. (1990) Transferrin Receptor Expression in Primary Superficial Human Bladder Tumours Identifies Patients Who Develop Recurrences. British Journal of Urology, 65, 339-344. https://doi.org/10.1111/j.1464-410X.1990.tb14752.x
|
[17]
|
Yang, D.C., Wang, F., Elliott, R.L., et al. (2001) Expression of Transferrin Receptor and Ferritin H-Chain mRNA Are Associated with Clinical and Histopathological Prognostic Indicators in Breast Cancer. Anticancer Research, 21, 541-549.
|
[18]
|
Wu, Y., Ma, Z., Mai, X., et al. (2022) Identification of a Novel Inhibitor of TfR1 from Designed and Synthesized Muriceidine a Derivatives. Antioxidants, 11, Article 834. https://doi.org/10.3390/antiox11050834
|
[19]
|
Tortorella, S. and Karagiannis, T.C. (2014) Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy. The Journal of Membrane Biology, 247, 291-307. https://doi.org/10.1007/s00232-014-9637-0
|
[20]
|
Han, L., Huang, R., Liu, S., et al. (2010) Peptide-Conjugated PAMAM for Targeted Doxorubicin Delivery to Transferrin Receptor Overexpressed Tumors. Molecular Pharmaceutics, 7, 2156-2165. https://doi.org/10.1021/mp100185f
|
[21]
|
Riaz, M.K., Zhang, X., Wong, K.H., et al. (2019) Pulmonary Delivery of Transferrin Receptors Targeting Peptide Surface-Functionalized Liposomes Augments the Chemotherapeutic Effect of Quercetin in Lung Cancer Therapy. International Journal of Nanomedicine, 14, 2879-2902. https://doi.org/10.2147/IJN.S192219
|
[22]
|
Dixit, S., Novak, T., Miller, K., et al. (2015) Transferrin Receptor-Targeted Theranostic Gold Nanoparticles for Photosensitizer Delivery in Brain Tumors. Nanoscale, 7, 1782-1790. https://doi.org/10.1039/C4NR04853A
|
[23]
|
Brandsma, M.E., Jevnikar, A.M. and Ma, S. (2011) Recombinant Human Transferrin: Beyond Iron Binding and Transport. Biotechnology Advances, 29, 230-238. https://doi.org/10.1016/j.biotechadv.2010.11.007
|
[24]
|
Liu, G., Mao, J., Jiang, Z., et al. (2013) Transferrin-Modified Doxorubicin-Loaded Biodegradable Nanoparticles Exhibit Enhanced Efficacy in Treating Brain Glioma-Bearing Rats. Cancer Biotherapy and Radiopharmaceuticals, 28, 691-696. https://doi.org/10.1089/cbr.2013.1480
|
[25]
|
Kim, T.H., Jo, Y.G., Jiang, H.H., et al. (2012) PEG-Transferrin Conjugated Trail (TNF-Related Apoptosis-Inducing Ligand) for Therapeutic Tumor Targeting. Journal of Controlled Release, 162, 422-428. https://doi.org/10.1016/j.jconrel.2012.07.021
|
[26]
|
Daniels, T.R., Bernabeu, E., Rodríguez, J.A., et al. (2012) The Transferrin Receptor and the Targeted Delivery of Therapeutic Agents against Cancer. Biochimica et Biophysica Acta (BBA)-General Subjects, 1820, 291-317. https://doi.org/10.1016/j.bbagen.2011.07.016
|
[27]
|
Luria-Pérez, R., Helguera, G. and Rodríguez, J.A. (2016) Antibody-Mediated Targeting of the Transferrin Receptor in Cancer Cells. Boletín Médico del Hospital Infantil de México, 73, 372-379. https://doi.org/10.1016/j.bmhimx.2016.11.004
|
[28]
|
Batra, J.K., Fitzgerald, D.J., Chaudhary, V.K., et al. (1991) Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv). Molecular and Cellular Biology, 11, 2200-2205. https://doi.org/10.1128/MCB.11.4.2200
|
[29]
|
Suzuki, S., Inoue, K., Hongoh, A., et al. (1997) Modulation of Doxorubicin Resistance in a Doxorubicin-Resistant Human Leukaemia Cell by an Immunoliposome Targeting Transferring Receptor. British Journal of Cancer, 76, 83-89. https://doi.org/10.1038/bjc.1997.340
|
[30]
|
Xu, L., Huang, C.-C., Huang, W., et al. (2002) Systemic Tumor-Targeted Gene Delivery by Anti-Transferrin Receptor ScFv-Immunoliposomes. Molecular Cancer Therapeutics, 1, 337-346.
|
[31]
|
Sugyo, A., Tsuji, A.B., Sudo, H., et al. (2015) Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. PLOS ONE, 10, e0123761. https://doi.org/10.1371/journal.pone.0123761
|
[32]
|
Pirollo, K.F., Nemunaitis, J., Leung, P.K., et al. (2016) Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Molecular Therapy, 24, 1697-1706. https://doi.org/10.1038/mt.2016.135
|
[33]
|
Kawabata, H. (2019) Transferrin and Transferrin Receptors Update. Free Radical Biology and Medicine, 133, 46-54. https://doi.org/10.1016/j.freeradbiomed.2018.06.037
|
[34]
|
Szwed, M., Matusiak, A., Laroche-Clary, A., et al. (2014) Transferrin as a Drug Carrier: Cytotoxicity, Cellular Uptake and Transport Kinetics of Doxorubicin Transferrin Conjugate in the Human Leukemia Cells. Toxicology in Vitro, 28, 187-197. https://doi.org/10.1016/j.tiv.2013.09.013
|
[35]
|
Barabas, K., Sizensky, J.A. and Faulk, W.P. (1991) Evidence in Support of the Plasma Membrane as the Target for Transferrin-Adriamycin Conjugates in K562 Cells. American Journal of Reproductive Immunology, 25, 120-123. https://doi.org/10.1111/j.1600-0897.1991.tb01078.x
|
[36]
|
Barabas, K., Sizensky, J.A. and Faulk, W.P. (1992) Transferrin Conjugates of Adriamycin Are Cytotoxic without Intercalating Nuclear DNA. Journal of Biological Chemistry, 267, 9437-9442. https://doi.org/10.1016/S0021-9258(19)50442-2
|
[37]
|
Beyer, U., Roth, T., Schumacher, P., et al. (1998) Synthesis and in vitro Efficacy of Transferrin Conjugates of the Anticancer Drug Chlorambucil. Journal of Medicinal Chemistry, 41, 2701-2708. https://doi.org/10.1021/jm9704661
|
[38]
|
Elliott, R.L., Stjernholm, R. and Elliott, M.C. (1988) Preliminary Evaluation of Platinum Transferrin (MPTC-63) as a Potential Nontoxic Treatment for Breast Cancer. Cancer Detection and Prevention, 12, 469-480.
|
[39]
|
Tanaka, T., Shiramoto, S., Miyashita, M., et al. (2004) Tumor Targeting Based on the Effect of Enhanced Permeability and Retention (EPR) and the Mechanism of Receptor-Mediated Endocytosis (RME). International Journal of Pharmaceutics, 277, 39-61. https://doi.org/10.1016/j.ijpharm.2003.09.050
|
[40]
|
Bejaoui, N., Page, M. and Nöel, C. (1991) Cytotoxicity of Transferrin-Daunorubicin Conjugates on Small Cell Carcinoma of the Lung (SCCL) Cell Line NCI-H69. Anticancer Research, 11, 2211-2213.
|
[41]
|
Friden, P.M., Walus, L.R., Musso, G.F., et al. (1991) Anti-Transferrin Receptor Antibody and Antibody-Drug Conjugates Cross the Blood-Brain Barrier. Proceedings of the National Academy of Sciences, 88, 4771-4775. https://doi.org/10.1073/pnas.88.11.4771
|
[42]
|
Wu, D. and Pardridge, W.M. (1996) Central Nervous System Pharmacologic Effect in Conscious Rats after Intravenous Injection of a Biotinylated Vasoactive Intestinal Peptide Analog Coupled to a Blood-Brain Barrier Drug Delivery System. Journal of Pharmacology and Experimental Therapeutics, 279, 77-83.
|
[43]
|
Zhang, Y. and Pardridge, W.M. (2005) Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor. Journal of Pharmacology and Experimental Therapeutics, 313, 1075-1081. https://doi.org/10.1124/jpet.104.082974
|
[44]
|
Penichet, M.L. and Morrison, S.L. (2004) Design and Engineering Human Forms of Monoclonal Antibodies. Drug Development Research, 61, 121-136. https://doi.org/10.1002/ddr.10347
|
[45]
|
Adams, G.P. and Weiner, L.M. (2005) Monoclonal Antibody Therapy of Cancer. Nature Biotechnology, 23, 1147-1157. https://doi.org/10.1038/nbt1137
|
[46]
|
Janeway, C., Travers, P., Walport, M., et al. (2001) Immunobiology: The Immune System in Health and Disease. Garland Publishing, New York. https://library.wur.nl/WebQuery/titel/1654235
|
[47]
|
Ng, P.P., Dela Cruz, J.S., Sorour, D.N., et al. (2002) An Anti-Transferrin Receptor-Avidin Fusion Protein Exhibits both Strong Proapoptotic Activity and the Ability to Deliver Various Molecules into Cancer Cells. Proceedings of the National Academy of Sciences, 99, 10706-10711. https://doi.org/10.1073/pnas.162362999
|
[48]
|
Kett, W.C., Osmond, R.I.W., Moe, L., et al. (2003) Avidin Is a Heparin-Binding Protein. Affinity, Specificity and Structural Analysis. Biochimica et Biophysica Acta (BBA)-General Subjects, 1620, 225-234. https://doi.org/10.1016/S0304-4165(02)00539-1
|
[49]
|
Moura, I.C., Lepelletier, Y., Arnulf, B., et al. (2004) A Neutralizing Monoclonal Antibody (mAb A24) Directed against the Transferrin Receptor Induces Apoptosis of Tumor T Lymphocytes from ATL Patients. Blood, 103, 1838-1845. https://doi.org/10.1182/blood-2003-07-2440
|
[50]
|
White, S., Taetle, R., Seligman, P.A., et al. (1990) Combinations of Anti-Transferrin Receptor Monoclonal Antibodies Inhibit Human Tumor Cell Growth in vitro and in vivo: Evidence for Synergistic Antiproliferative Effects. Cancer Research, 50, 6295-6301.
|
[51]
|
Crépin, R., Goenaga, A.-L., Jullienne, B., et al. (2010) Development of Human Single-Chain Antibodies to the Transferrin Receptor that Effectively Antagonize the Growth of Leukemias and Lymphomas. Cancer Research, 70, 5497-5506. https://doi.org/10.1158/0008-5472.CAN-10-0938
|
[52]
|
Taetle, R. and Honeysett, J.M. (1987) Effects of Monoclonal Anti-Transferrin Receptor Antibodies on in vitro Growth of Human Solid Tumor Cells. Cancer Research, 47, 2040-2044.
|
[53]
|
Petrini, M., Pelosi-Testa, E., Sposi, N.M., et al. (1989) Constitutive Expression and Abnormal Glycosylation of Transferrin Receptor in Acute T-Cell Leukemia. Cancer Research, 49, 6989-6996.
|
[54]
|
Taetle, R., Rhyner, K., Castagnola, J., et al. (1985) Role of Transferrin, Fe, and Transferrin Receptors in Myeloid Leukemia Cell Growth. Studies with an Antitransferrin Receptor Monoclonal Antibody. Journal of Clinical Investigation, 75, 1061-1067. https://doi.org/10.1172/JCI111768
|
[55]
|
Brooks, D., Taylor, C., Dos Santos, B., et al. (1995) Phase Ia Trial of Murine Immunoglobulin a Antitransferrin Receptor Antibody 42/6. Clinical Cancer Research, 1, 1259-1265.
|
[56]
|
Chiu, S.-J., Liu, S., Perrotti, D., et al. (2006) Efficient Delivery of a Bcl-2-Specific Antisense Oligodeoxyribonucleotide (G3139) via transferrin Receptor-Targeted Liposomes. Journal of Controlled Release, 112, 199-207. https://doi.org/10.1016/j.jconrel.2006.02.011
|
[57]
|
Nam, J.-P., Park, S.-C., Kim, T.-H., et al. (2013) Encapsulation of Paclitaxel into Lauric Acid-O-Carboxymethyl Chitosan-Transferrin Micelles for Hydrophobic Drug Delivery and Site-Specific Targeted Delivery. International Journal of Pharmaceutics, 457, 124-135. https://doi.org/10.1016/j.ijpharm.2013.09.021
|
[58]
|
Huang, Y., He, L., Liu, W., et al. (2013) Selective Cellular Uptake and Induction of Apoptosis of Cancer-Targeted Selenium Nanoparticles. Biomaterials, 34, 7106-7116. https://doi.org/10.1016/j.biomaterials.2013.04.067
|